{
    "ticker": "CGNT",
    "name": "Cogent Biosciences, Inc.",
    "description": "Cogent Biosciences, Inc. is a biotechnology company focused on developing transformative therapies for patients with genetically defined diseases. Founded in 2015 and based in Cambridge, Massachusetts, Cogent is dedicated to harnessing the power of genetics to create precision medicine solutions. The company's lead program is aimed at treating patients with rare genetic disorders, particularly those caused by mutations in the KIT gene, which is associated with various cancers and other serious health conditions. Cogent's innovative approach combines advanced genetic insights with cutting-edge drug development techniques to identify and validate unique therapeutic targets. By leveraging its proprietary platform, the company aims to expedite the discovery and development of effective treatments that address the underlying causes of disease. Cogent is committed to improving patient outcomes and enhancing the quality of life for individuals affected by rare genetic disorders.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2015",
    "website": "https://www.cogentbio.com",
    "ceo": "Robert H. Johnson",
    "social_media": {
        "twitter": "https://twitter.com/CogentBio",
        "linkedin": "https://www.linkedin.com/company/cogent-biosciences/"
    },
    "investor_relations": "https://ir.cogentbio.com",
    "key_executives": [
        {
            "name": "Robert H. Johnson",
            "position": "CEO"
        },
        {
            "name": "David A. Dyer",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "CGT-1"
            ]
        }
    ],
    "seo": {
        "meta_title": "Cogent Biosciences, Inc. | Transforming Genetic Medicine",
        "meta_description": "Explore Cogent Biosciences, a leader in biotechnology focused on developing innovative therapies for genetically defined diseases. Learn about our mission and pipeline.",
        "keywords": [
            "Cogent Biosciences",
            "Biotechnology",
            "Genetic Disorders",
            "Precision Medicine",
            "Therapeutics"
        ]
    },
    "faq": [
        {
            "question": "What does Cogent Biosciences do?",
            "answer": "Cogent Biosciences develops transformative therapies for patients with genetically defined diseases."
        },
        {
            "question": "Who is the CEO of Cogent Biosciences?",
            "answer": "Robert H. Johnson is the CEO of Cogent Biosciences, Inc."
        },
        {
            "question": "Where is Cogent Biosciences headquartered?",
            "answer": "Cogent Biosciences is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What is Cogent's lead program?",
            "answer": "Cogent's lead program is focused on treating patients with rare genetic disorders, particularly those associated with mutations in the KIT gene."
        },
        {
            "question": "When was Cogent Biosciences founded?",
            "answer": "Cogent Biosciences was founded in 2015."
        }
    ],
    "competitors": [
        "CRSP",
        "EDIT",
        "SGEN",
        "ALNY"
    ],
    "related_stocks": [
        "MRNA",
        "NVAX",
        "BNTX",
        "GILD"
    ]
}